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Current therapies for Traumatic brain injury (TBI) focus on stabilizing individuals and
on preventing further damage from the secondary consequences of TBI. A major
complication of TBI is cerebral edema, which can be caused by the loss of blood
brain barrier (BBB) integrity. Recent studies in several CNS pathologies have shown
that activation of latent platelet derived growth factor-CC (PDGF-CC) within the brain
can promote BBB permeability through PDGF receptor α (PDGFRα) signaling, and that
blocking this pathway improves outcomes. In this study we examine the efficacy for
the treatment of TBI of an FDA approved antagonist of the PDGFRα, Imatinib. Using
a murine model we show that Imatinib treatment, begun 45 min after TBI and given
twice daily for 5 days, significantly reduces BBB dysfunction. This is associated with
significantly reduced lesion size 24 h, 7 days, and 21 days after TBI, reduced cerebral
edema, determined from apparent diffusion co-efficient (ADC) measurements, and with
the preservation of cognitive function. Finally, analysis of cerebrospinal fluid (CSF) from
human TBI patients suggests a possible correlation between high PDGF-CC levels and
increased injury severity. Thus, our data suggests a novel strategy for the treatment of
TBI with an existing FDA approved antagonist of the PDGFRα.
Keywords: traumatic brain injury, TBI outcome, blood brain barrier, platelet derived growth factor-CC, platelet
derived growth factor receptor α, Imatinib, cerebral edema, Morris water maze
Introduction
The Centers for Disease Control estimate that every year in the United States approximately
2.5 million people sustain a Traumatic brain injury (TBI). There are approximately 53,000 TBI
related deaths and 283,000 hospitalizations annually, with many patients suffering permanent
disability (Frieden et al., 2014). Additionally, TBI is a contributing factor in nearly a third
of all injury-related deaths in the United States and is a leading cause of death in North
America for individuals between the ages of 1–45 (Rutland-Brown et al., 2006; Hemphill and
Phan, 2013b; Byrnes et al., 2014). TBI also accounts for more lost work time than cancer and
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cardiovascular diseases combined (Thurman et al., 1999; Ma
et al., 2014). Over the past two decades our understanding of
the complex pathobiology of TBI has improved significantly.
However, despite numerous studies in animal models of TBI
and clinical trials of various therapeutic strategies, no effective
therapy for TBI patients has emerged (Grumme et al., 1995;
Marmarou et al., 1999; Bramlett and Dietrich, 2004; Yurkewicz
et al., 2005; Maas et al., 2006, 2010). The pathophysiology of
TBI is complex and involves both primary and secondary insults
(Hemphill and Phan, 2013b; Finnie, 2014). Primary injury to
the brain can be induced by numerous mechanisms, such as
brain contusion, hematoma, and shearing or stretching of the
brain tissue caused by motion of the brain structures relative to
the skull. Secondary injury development includes multifaceted
biochemical and physiological processes that are initiated by the
primary insult and manifest over a period of hours to days and
even months (Cernak, 2005; Finnie, 2014; Logsdon et al., 2015).
The lack of effective pharmacological treatments for TBI
patients despite the many clinical trials in the past two decades
suggests that the development of improved therapies for the
treatment of TBI will depend upon a better understanding
of the underlying mechanisms that drive secondary neuronal
injury during the acute phase of TBI. One of the most
serious and difficult to control secondary effects of TBI is
the development of cerebral edema. Cerebral edema leads
to brain swelling and increased intracranial pressure (ICP),
which in severe cases can result in cistern compression, brain
herniation, and even death. The causes of edema in TBI
patients are complex but it is well appreciated that the loss
of the blood brain barrier (BBB) is a significant factor in
the development of vasogenic edema (Chodobski et al., 2011).
Our recent studies, and those of others, have shown that
signaling through the PDGF receptor α (PDGFRα) in the
neurovascular unit (NVU) can promote BBB permeability and
neuronal injury in several different neuropathological settings,
including ischemic and hemorrhagic stroke, spinal cord injury,
MS, and seizures (Su et al., 2008; Ma et al., 2011; Abrams
et al., 2012; Adzemovic et al., 2013; Fredriksson et al., 2015).
In our previous studies of ischemic stroke we have found that
the protease tissue-type plasminogen activator (tPA) induces
opening of the BBB through proteolysis of latent platelet
derived growth factor-CC (PDGF-CC), generating an active
form of PDGF-CC that binds to the PDGFRα and induces
cell signaling (Su et al., 2008). The PDGFRα is localized to
astrocytes in the NVU (Su et al., 2008; Fredriksson et al.,
2015), and blocking this pathway with either the PDGFRα
antagonist Imatinib or neutralizing antibodies to PDGF-
CC reduces BBB dysfunction and improves outcome after
ischemic stroke (Su et al., 2008). Similar results have been
obtained by blocking PDGFRα signaling in animal models
of hemorrhagic stroke, spinal cord injury, MS, and seizures
(Ma et al., 2011; Abrams et al., 2012; Adzemovic et al., 2013;
Fredriksson et al., 2015). These latter studies suggest that
blocking PDGFRα signaling may provide benefit in diverse CNS
pathologies through protection of the BBB. Consistent with this
suggestion our recent work indicates that tPA can promote
post-traumatic cerebrovascular damage including increased BBB
leakage (Sashindranath et al., 2012). However, it is not known
whether the PDGFRα pathway also plays a role in TBI-related
injuries.
In the study presented here we used two versions of a well-
establishedmouse model of TBI, controlled cortical impact (CCI;
Sinz et al., 1999; Gilmer et al., 2008; Loane et al., 2009) to
demonstrate for the first time that Imatinib treatment after TBI
reduces BBB opening and significantly improves outcomes. Our
data suggest that PDGF signaling contributes to the development
of vasogenic edema by increasing BBB opening after TBI and
that both vasogenic edema and cognitive impairment can be
reduced by Imatinib treatment. These findings identify novel
targets for TBI treatment and contribute to our understanding
of the relationship between BBB leakage and the downstream
secondary injuries associated TBI. In addition, we demonstrate
the potential effectiveness of Imatinib, an existing FDA approved
inhibitor of the PDGFRα pathway, for the treatment of acute TBI,
suggesting the possibility of rapid translation of these results.
Material and Methods
TBI Models
Ten-week-old male C57BL/6J mice were anesthetized with 2%
isoflurane and placed in a stereotatic frame (Kopf, Tujunga,
CA, USA). Core body temperatures were maintained at 37.0◦ C
for the entire procedure. For the unilateral TBI experiments, a
3.5 mm craniotomy was made over the right parietotemporal
cortex with an electric drill (Harvard Apparatus) and the bone
flap was removed. Vertically directed CCI was performed using
a pneumatic impactor (Precision Systems and Instrumentation,
VA) with a 3 mm flat-tip. The impact speed, tissue displacement
and impact duration were set at 3.65m/s, 1 mm, and 400 ms
respectively. A cap made from Dental Acrylic was glued to cover
the craniotomy. To generate a larger bilateral injury, a previously
described TBI model was used where the CCI is delivered to
the midline (Liu et al., 2013). For this model a 5 mm circular
craniotomy was made with center near bregma −2.5 and the
impact speed, tissue displacement and impact duration were set
at 3.00m/s, 1.1 mm, and 50 ms respectively. After the impact, the
circular bone fragment from the craniotomy was glued back to
the cranial window. For the unilateral TBI experiments, animal
group sizes were n = 10 for the Evans blue (EB) Assays, n =
6 in the T2 and apparent diffusion co-efficient (ADC) analysis,
and n = 5 for volumetric tissue loss after 21 days. In the
bilateral TBI experiments, animal group sizes were n = 5 in
the T2 and ADC analysis, n = 5 for volumetric tissue loss after
21 days, and n = 7–9 in the Morris water maze (MWM) studies.
Separate groups of animals were used in each experiment and
were not overlapped with the exception that the T2 and ADC
analysis at 24 h and 7 days were performed on the same mice.
For sham surgeries, all animals underwent the same surgical
procedures except the craniotomy and CCI. All animals received
the analgesic carprofen (5 mg/kg by subcutaneous injection)
immediately prior to surgery, and post-surgery care consistent
with the ‘‘Guide for the Care and Use of Laboratory Animals’’.
Briefly, mice were kept on a 37◦C warming pad overnight
during recovery and were monitored daily for any distress
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behavior until the end of the study, receiving analgesics after
surgery as needed. All animal experiments were approved by
the University Committee on Use and Care of Animals at the
University of Michigan, and conducted in accordance with the
United States Public Health Service’s Policy on Humane Care
and Use of Laboratory Animals. In general, the mice tolerated the
procedures well. They were lethargic in the first few hours after
surgery, and mice with the bilateral injury took longer to recover
from anesthesia than mice in the unilateral model and remained
lethargic for a longer period of time during the first day. There
were no deaths or other complications with the unilateral model,
but there was 1 death out of 52 mice subjected to the bilateral
injury.
Evans Blue Analysis
For analysis of cerebrovascular permeability after TBI, mice were
injected with 100 microliters of 4% EB (intravenous, Sigma-
Aldrich) in lactated Ringer’s solution 1 h before the animals
were sacrificed by transcardial perfusion with phosphate buffered
saline (PBS) for 8 min. The brains were removed and separated
into hemispheres ipsilateral and contralateral to the TBI. Each
hemisphere was then homogenized in N, N-dimethylformamide
(Sigma-Aldrich) and centrifuged for 45 min at 25,000 rcf. The
supernatants were collected and quantitation of EB extravasation
performed as described (Yepes et al., 2003). Briefly, EB levels in
each hemisphere were determined from the formula:
(A620nm − ((A500nm+A740nm) /2)) /mgwetweight.
MRI Scan
After CCI, animals were anesthetized with 2% isoflurane/air
mixture for T2 scans (7.0T Varian MR, 183 mm horizontal
bore, Varian, Palo Alto, CA, USA). A double-tuned volume
radiofrequency coil was used to scan the head region of the
mice. Axial T2-weighted images were acquired using a fast spin-
echo sequence with the following parameters: repetition time
(TR)/effective echo time (TE), 4000/60 ms; echo spacing, 15 ms;
number of echoes, 8; field of view (FOV), 20 × 20 mm; matrix,
256 × 128; slice thickness, 0.5 mm; number of slices, 25; and
number of scans, 1. The protocol for diffusion weighted imaging
(DWI) utilized the following parameters: TR/TE, 4000/47 ms;
FOV, 20 × 20 mm; matrix, 128 × 64 and the same slice package
as the above spin-echo sequence.
For the data analysis, Image J software (NIH) was used to
calculate the lesion volume from T2 scan, and Matlab software
(MathWorks, Natick, MA, USA) was used to calculate the
apparent diffusion coefficient from DWI scan. To calculate
volumetric tissue loss 21 days after TBI, ROIs from MRI slices
corresponding to the hippocampal region were calculated by
Image J. The volume scales used (mm3) for all T2 scans were the
same in each model.
Imatinib Treatment
To block PDGFRα activation, mice were treated twice daily by
oral gavage with the tyrosine kinase inhibitor Imatinib (200
mg/kg) starting 45 min after TBI and repeated for 5 days.
Lactated Ringer’s solution was used as vehicle control.
Histology
Deeply anaesthetized mice were perfused transcardially
21 days after TBI with PBS for 2 min and followed by 4%
paraformaldehyde for 5 min. After perfusion, the brains were
quickly removed from the skull and post-fixed for 1 h in buffered
4% paraformaldehyde (+4 ◦C), and embedded in OCT and
stored at –70 ◦C until cut. Brains were cut in 14 µm-thick
coronal sections with a sliding microtome and stained with
hematoxylin and eosin. Images were visualized using Nikon
Eclipse TE-2000e and captured with a digital camera (Q-Imaging
Micropubliser RTV version 5.0). These captured images from
each section were then stitched together by metamorph software
(version 7.7.4.0).
Morris Water Maze
The MWM was performed as previously described (McKinney
et al., 2008; White et al., 2008; Perkowski and Murphy, 2011).
The pool was 1.2 meters in diameter and filled with water
made opaque with white non-toxic paint. The escape platform
consisted of a 10 cm platform that was submerged 0.5 cm below
the surface of the water in the center of one of the quadrants.
Water was maintained at 25 ± 2◦ C. The walls surrounding the
pool were adorned with high-contrast posters for use as distal
cues. The room was lit by indirect white light (200 lux in center
of pool).
For 10 days prior to training, mice were handled for 2–3 min
once daily. Every training trial began with the mouse on the
platform for 15 s. The mouse was then placed into the water
facing the wall of the pool and allowed to search for the
platform. The trial ended either when the mouse climbed onto
the platform or when 60 s had elapsed. At the end of each trial
the mouse was allowed to rest on the platform for 15 s. Mice
were given 6 trials per day (in blocks of two trials, 1 min inter-
trial intervals and 1 h inter-block intervals) for 4 days, with
the starting position chosen pseudo-randomly among 6 start
positions. A probe trial was conducted 24 h after the end of
training (on day 5). During the probe trial, the escape platform
was removed and mice were placed in the pool at the start
location directly opposite of where the platform was previously
located and allowed to swim for 60 s. To control for motivation
and sensory deficits mice were also examined in the visible-
platform version of the MWM 24 h after the probe trial. The
visible-platform version consisted of a single day of training
with 6 trials during which the platform was moved to a new
location and marked with a distinct local cue. All MWM data
was acquired with a digital video camera 1.5 meters from the
water surface. Images from the digital camera were processed
and stored on a desktop PC using Actimetrics WaterMaze
Software (Actimetrics, Wilmette, IL). Water maze performance
was quantified using proximity. Proximity measurements were
calculated by the tracking software at a rate of 1 Hz as the
instantaneous distance (in centimeters) from the designated
platform location. We prefer to use proximity measures because
they are independent of swim speed (Gallagher et al., 1993) and
moreover, the average proximity measure is the most sensitive
probe trial measurement (Maei et al., 2009). Performance during
training was assessed using a cumulative proximity measure.
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Cumulative proximity is the sum of all of the instantaneous
distance measurements minus the distance calculated as a perfect
swim path which is represented as a straight line between the
start location and the platform location. Performance during the
probe trial was assessed using an average proximity measure.
Average proximity is the average of all of the instantaneous
distance measurements recorded during the probe trial with
lower values reflecting a more selective search strategy.
Human CSF Samples
This study was conducted in accordance with the National
Health and Medical Research Council of Australia National
Statement on Ethical Conduct in Research Involving
Humans and approved by Human Ethics Committees of
the Alfred Hospital and Austin Hospital, Melbourne, Australia.
Cerebrospinal fluid (CSF) was obtained from 17 TBI patients (16
male; 1 female) aged between 15 and 58 years (mean 31.1 years)
recruited via the Trauma Service of the Alfred Hospital with
delayed informed consent. Patients who required an external
ventricular drain (EVD) for monitoring ICP were included. The
CSF was collected within the first 36 h of admission in bags over
24 h in cooled containers then centrifuged at 2000 g for 15 min
at 4◦C and stored at –80◦C. Non-TBI control CSF samples
obtained from 4 patients recruited to the Alfred hospital for
elective neurosurgery, or via lumbar puncture from 5 patients
recruited to the Austin Hospital (Melbourne) suspected of
having multiple sclerosis. CSF samples were centrifuged as above
and the supernatants stored at−80◦C.
Western blot analysis was performed to detect PDGF-CC
levels in human CSF samples. CSF (30 µl of undiluted CSF)
were subjected to SDS-PAGE electrophoresis under denaturing
conditions and transferred to nylon membranes using standard
conditions. To detect PDGF-CC, membranes were hybridized
with a polyclonal goat anti-human PDGF-C antibody (RnD
Systems, AF1560) diluted 1:200. After washing, membranes
were hybridized with HRP tagged secondary rabbit anti-goat
IgG antibody (1:5000 dilution). PDGF-CC signals were revealed
using enhanced chemiluminescence (SuperSignal West Pico;
Thermo Scientific, Rockford, IL, USA). The relative amount
of PDGF-CC in each sample was estimated from the intensity
of the PDGF-CC band in each lane and assigned a value
from 0 to 10, with 0 being undetected and 10 being the most
intense. The average for all the samples at each extended glasgow
outcome scale (GOSE) score was plotted against the GOSE
score.
Statistical Analysis
The data are presented as mean ± SEM. All statistical analysis
was performed using GraphPad Prism statistical software.
Significant outliers were identified and excluded based on
Grubb’s test with significance level alpha set to 0.05. Analysis
for significance was performed as indicated in the figure legends.
All neuropathology experiments were repeated at least two
independent times and n indicates the number of individual
mice used in the study. P values less than 0.05 were considered
statistically significant and are indicated in the figures by an
asterisk.
Results
Imatinib Inhibits the BBB Leakage after TBI
Since both TBI and ischemic stroke share the common
pathophysiologic mechanisms of loss of BBB control and the
development of cerebral edema (Bouma et al., 1991; Marion
et al., 1991; Zauner et al., 1996; Bramlett and Dietrich, 2004;
Lescot et al., 2010), we hypothesized that, as is the case with
ischemic stroke, PDGFRα signaling might also play a role
in TBI. To test this hypothesis we investigated if blocking
PDGFRα signaling after TBI could reduce BBB leakage. For
these studies we examined the efficacy of treatment with the
PDGFRα antagonist Imatinib in mice subjected to CCI in the
right parietotemporal cortex. The mice were treated with either
vehicle or 200 mg/kg of Imatinib by gavage 45 min after CCI
and again 22 h after injury. The mice were then analyzed for
BBB integrity by EB extravasation 24 h after TBI. We predicted
that if PDGFRα signaling contributes to loss of BBB integrity
after TBI then Imatinib treatment should result in less BBB
leakage 24 h after TBI. Consistent with our hypothesis, we found
that compared to vehicle-treated controls, Imatinib treatment
significantly reduced EB leakage in the ipsilateral hemisphere
24 h after TBI (Figures 1A,B >70%). We also found that the
injury resulted in BBB leakage in the contralateral hemisphere,
but at levels that were nearly 8-fold lower than in the ipsilateral
hemisphere (3.4 ± 0.6 ipsi vs. 0.43 ± 0.08 contra). Similar to the
effects observed in the ipsilateral hemisphere Imatinib treatment
was also effective at reducing BBB leakage in the contralateral
hemisphere (Figure 1C >75%). These results demonstrate that
like its effects in stroke, spinal cord injury and MS (Su et al.,
2008; Ma et al., 2011; Abrams et al., 2012; Adzemovic et al.,
2013), Imatinib treatment preserves BBB integrity following
TBI.
Imatinib Reduces Lesion Size and Vasogenic
Edema after TBI
Since brain edema is a common and serious consequence of
TBI that contributes to lesion expansion and secondary brain
damage (Dietrich et al., 1994; del Zoppo and Mabuchi, 2003)
and since the rise in edema after TBI is thought to be due, at
least in part, to the loss of the BBB control, we examined if
Imatinib treatment also reduced lesion size and edema 24 h and
7 days after TBI. For these studies mice were subjected to CCI
in the right parietotemporal cortex and then treated with either
vehicle or 200 mg/kg of Imatinib by gavage 45 min after TBI
and then twice a day for 5 days following injury. T2 and DWI
MRI scans were obtained at 24 h and 7 days post-injury. The T2
scans were used to calculate the lesion volume and showed that
by 24 h after CCI there was conspicuous tissue damage within
the region surrounding the impact site (Figure 2A). The T2
scans also revealed that by 7 days post-injury there was extensive
tissue loss and cavitation in the cortex of untreated mice that was
significantly reduced in the Imatinib treated group (Figure 2A).
Quantification of these data demonstrated that at 24 h after injury
the mean T2 lesion volume was 22.7 ± 2.9 mm3 in the vehicle-
treated group and 11.1± 1.2 mm3 in the Imatinib-treated group.
By 7 days after injury, the T2 signal was reduced in both groups.
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FIGURE 1 | Imatinib reduces blood brain barrier (BBB) leakage after Traumatic brain injury (TBI). Mice were treated with vehicle or Imatinib (200 mg/kg,
daily p.o. for 1 day) starting 45 min after unilateral controlled cortical impact (CCI). Twenty three hours after unilateral CCI, Evans blue (EB) dye was injected
intravenously as a bolus and animals were perfused with phosphate buffered saline (PBS) 1 h later. (A) Representative brains from vehicle and Imatinib treated
animals are shown. (B,C) Quantitative analysis of EB leakage in the ipsilateral (B) and contralateral (C) hemispheres. Data are expressed as mean ± SEM (n = 10)
and double asterisks indicate p < 0.01.
However, the Imatinib-treated mice still showed a significant
reduction in lesion size of approximately 50% compared to the
vehicle-treated group (12.5 ± 2.4 mm3 vs. 6.0 ± 0.8 mm3,
Figure 2B).
To examine the effect of Imatinib treatment on edema in
the injured hemisphere, the DWI scans of these mice were
used to calculate hemispheric ADC values, which measure the
impedance of water molecule diffusion within tissue. These
results are shown in Figure 2C. In both groups the ADC values
were reduced by 24 h after TBI compared to uninjured mice
(Rau et al., 2006) (the normal ADC value is shown by the dashed
line in Figure 2C). This indicates the presence of cytotoxic
edema in both vehicle- and Imatinib-treated mice that was
not significantly different between the groups. By day 7 there
was a pseudo-correction of the ADC above the normal value
indicating the development of vasogenic edema in the vehicle-
treated mice. However, in the Imatinib-treated group the ADC
value was significantly lower, indicating that there was much less
vasogenic edema 7 days after injury in Imatinib treated mice
(0.944± 0.065 mm2/s vs. 0.799± 0.046 mm2/s, Figure 2C).
Imatinib Reduces Cavitation and Tissue Loss
after TBI
Since neuronal loss in the hippocampus has been linked to
pathological outcomes of TBI in both humans (Tate and
Bigler, 2000; Swartz et al., 2006) and in animal models of
TBI (McIntosh et al., 1989; Dixon et al., 1991; Lowenstein
et al., 1992; Hall et al., 2008), we next investigated whether
intervention in the acute phase of TBI with 5 days of
Imatinib treatment translated into long term tissue preservation.
For these studies mice were subjected to CCI in the right
parietotemporal cortex and then treated with either vehicle
or 200 mg/kg of Imatinib by gavage 45 min after CCI and
then twice a day for 5 days following injury. Previous studies
have demonstrated that hippocampal neurons undergo regional
alterations and remodeling after TBI (Witgen et al., 2005;
Cohen et al., 2007). Consistent with this, hematoxylin and
eosin staining of brain sections showed that there was dramatic
tissue loss and remodeling in the cortex and hippocampus
21 days after TBI, including large cavitations (Figure 3A).
As with BBB permeability, lesion size, and vasogenic edema,
Imatinib substantially reduced cavitations (Figure 3B). To
quantify the extent of the cavitations, MRI T2 scans were
performed 21 days after TBI. These scans confirmed the loss
of tissue noted in the H&E stains, showing large areas of
hyper-intense signals indicative of cavitation (Figures 3C,D).
Quantification of the hyper-intense signals showed that Imatinib
treatment significantly reduced tissue loss (vehicle 3.6± 0.3 mm3
vs, Imatinib 2.3 ± 0.4 mm3 Figure 3E). This suggests that
early intervention with Imatinib may impact long term TBI
progression.
Imatinib Protects in a Bilateral TBI Model
Since neuronal loss and remodeling can affect long termmemory
and cognitive function, mice that were subjected to an identical
injury and treatment were subsequently examined in the MWM
test. However, neither the vehicle- nor the Imatinib-treated
mice showed a consistent deficit, suggesting that the injury
to one hemisphere may not be extensive enough to result in
measurable behavioral changes (not shown). Consistent with
this interpretation several studies have suggested that when
an undamaged unilateral hippocampus is present, behavioral
changes in mice are minimized in memory and cognition
tests (Shipton et al., 2014). Based on these recent studies, we
hypothesize that the lack of significance in our MWM test is due
to the presence of an intact hippocampus on the contralateral
side resulting in the lack of a measureable cognitive deficit
in the control cohort. We therefore extended our study with
a second, more severe, TBI model where CCI is delivered
to the midline producing a larger bilateral TBI (Liu et al.,
2013).
To characterize the extent of injury in the midline CCI model
and to examine the potential efficacy of Imatinib in a more severe
model of TBI we performed midline CCI followed by Imatinib
treatment and analyses as above. Briefly, mice were gavaged
45 min after TBI and then twice a day for 5 days following
injury with either vehicle or 200 mg/kg of Imatinib. T2 and DWI
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FIGURE 2 | Imatinib reduces lesion volume and edema after TBI. Mice
were treated with vehicle or Imatinib (200 mg/kg, twice daily p.o. for 5 days)
starting 45 min after unilateral CCI and examined for lesion volume and
cerebral edema by MRI 24 h and 7 days after unilateral CCI. (A)
Representative T2-weighted MRI images. (B) Quantitative analysis of the
lesion volume determined from theT2-weighted hyper-intense signal. (C) The
relative extent of cerebral edema in the ipsilateral hemisphere was determined
by calculating the apparent diffusion co-efficient (ADC) values from diffusion
weighted imaging (DWI) scans. Data are expressed as mean ± SEM (n = 6);
single asterisk indicates p < 0.05, double asterisks indicate p < 0.01, and the
dotted line indicates the normal ADC value of 736 × 10−3 mm2/s reported for
age matched mice (Rau et al., 2006).
MRI scans were obtained at 24 h and 7 days post-injury. Lesion
volumes were calculated from the T2 scans (Figures 4A,B). As
expected, the midline CCI resulted in a bilateral injury that was
nearly twice as large as the unilateral injury at 24 h after CCI
(39.8± 5.6 mm3 vs. 22.7± 2.9 mm3) and remained larger 7 days
after injury (18.9 ± 3.2 mm3 vs. 12.5 ± 2.4 mm3) (compare
Figure 2B with Figure 4B). Imatinib treatment was also effective
at reducing lesion size in the midline CCI model, producing
a non-significant trend toward a smaller lesion at 24 h but
a significant decrease in lesion volume by 7 days post injury
(18.9± 3.2 mm3 vs. 8.0± 3.2 mm3).
ADC analysis was also performed with this model; however
unlike the unilateral model where the ADC values were
calculated only in the injured hemisphere, in the bilateral
TBI model the ADC values were calculated for the entire
brain. Similar to the lesion size, both cytotoxic and vasogenic
edema were increased in the midline CCI model compared to
unilateral CCI model (compare Figures 2C–4C). These data also
demonstrated that even with the more severe injury, Imatinib
treatment was effective at reducing both cytotoxic edema at 24 h
after injury (0.559 ± 0.009 mm2/s vs. 0.635 ± 0.018 mm2/s) and
vasogenic edema at day 7 (1.577 ± 0.040 mm2/s vs. 1.391 ±
0.028 mm2/s) (the normal ADC value is shown by the dashed
line in Figure 4C).
Mice subjected to midline CCI were also analyzed for long
term loss of neuronal tissue due to cavitation 21 days after
injury. These data are shown in Figure 5 and indicate that unlike
the differences in initial lesion size, that were nearly 2-fold at
24 h after injury (39.8 ± 5.6 mm3 vs. 22.7 ± 2.9 mm3), the
final difference in tissue loss due to cavitation was only ∼9%
between the two models (3.9 ± 0.3 mm3 vs. 3.6 ± 0.3 mm3,
compare Figures 3E, 5E). Nonetheless, H&E staining of brain
sections showed that there was muchmore hippocampal loss and
remodeling in the bilateral TBI model compared to the unilateral
model, where the left hippocampus remained largely intact
(compare Figures 3A–5A). Similar to the results in lesion size,
and edema, Imatinib treatment significantly reduced cavitations
in the bilateral TBI model (Figures 5D,E) and appeared to
preserve hippocampal structure (Figure 5B). This suggests that
even in a severe model of TBI early intervention with Imatinib
may have long term benefit in TBI.
Imatinib Preserves Cognitive Function after
Bilateral TBI
Cognitive function in mice exposed to midline CCI was assessed
by examining spatial learning and memory in the MWM.
Data comparing mice with bilateral CCI to Sham treated
mice are presented in Figures 6A,C,E,G. Data comparing
injured mice treated with Imatinib or vehicle are presented
in Figures 6B,D,F,H. All data are presented in terms of
proximity which is a measure of ‘‘search error’’ and therefore
lower scores indicate a more selective search strategy. Mice
in the Sham group exhibited typical performance across the
four days of training (Figure 6A) during which time their
cumulative proximity scores significantly decreased. Conversely,
the performance of mice in the TBI group did not improve
over time and was significantly worse compared to the Sham
group (p < 0.001). To assess long-term memory, a probe
trial was conducted 24 h after the last training trial was
completed on day 4. Similar to the cumulative proximity, the
average proximity measure is a search error measure which
is independent of swim speed. The duration of the probe
trial is fixed at 60 s; therefore an average measure is made
(c.f. cumulative for the variable length training trials). Again,
a lower number indicated a more selective search strategy.
Injured mice in the TBI group were significantly impaired
when compared to the mice in the Sham treated group.
In addition, the injured mice in the TBI group performed
significantly worse even when the platform was clearly marked
(Figure 6E) and exhibited slower swim speeds during the
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FIGURE 3 | Imatinib reduces tissue loss after TBI. Mice were treated with vehicle or Imatinib (200 mg/kg, twice daily p.o. for 5 days) starting 45 min after
unilateral CCI. Twenty one days later, animals underwent MRI T2 scan and then were perfused and fixed in paraformaldehyde and stained with H&E. (A,B)
Representative photomicrographs of coronal sections near bregma −1.5 (10× objective) from vehicle-treated (A) and Imatinib-treated (B) mice. (C,D) Representative
T2-weighted MRI images from vehicle-treated (C) and Imatinib-treated mice (D). (E) Quantification of volumetric loss of tissue determined from theT2-weighted
hyper-intense signal. Data are expressed as mean ± SEM (n = 5) and the single asterisk indicates p < 0.05.
probe trial (Figure 6G). In a separate experiment, mice were
exposed to bilateral CCI and then treated with either vehicle
or 200 mg/kg of Imatinib by gavage 45 min after CCI and
then twice a day for 5 days prior to the start of the water
maze. Across the 4 days of training (Figure 6B) injured mice
that were treated with Imatinib exhibited significantly better
performance when compared to the vehicle treated mice (p
< 0.01). Similarly, mice treated with Imatinib outperformed
vehicle treated mice during the probe trial (Figure 6D).
Treatment with Imatinib did not alter performance on the visible
platform version of the water maze (Figure 6F) or swim speed
(Figure 6H).
PDGF-CC is Increased in Human CSF after TBI
Although our data suggest that the BBB leakage, controlled by
PDGF signaling in the NVU, may contribute to TBI progression
in animal models, it is not known if PDGF-CC protein levels
are altered in human TBI. Therefore, we examined PDGF-
CC levels in the CSF of human TBI patients and in control
non-TBI patients by immunoblotting. For these studies we
obtained CSF from 17 TBI patients and 9 non-TBI patients.
The TBI patients had GOSE ranging from 1 to 8, where 1
is the most severe, indicating that the patient died of their
injuries, and 8 is the mildest injury and the patients have
a good recovery (Lu et al., 2010). Immunoblot analysis of
these samples is shown in Figure 7 along with a platelet
releasate sample as a positive control for PDGF-CC. Note that
the lanes with the strongest PDGF-CC signal are all from
TBI patients with the lowest (most severe) GOSE scores. The
relative intensity of the PDGF-CC staining in each lane was
ranked from 0 to 10 for both the TBI patients and non-TBI
patients with 0 being undetectable and 10 representing the most
intense PDGF-CC staining, and these data were then plotted
against the GOSE score (Figure 7B). This semi-quantitative
analysis suggests that there may be a correlation between TBI
severity and the presence of PDGF-CC in the CSF. These
data are also similar to a positive correlation reported between
PDGF-CC levels in plasma and worse outcomes in ischemic
stroke patients (Rodríguez-González et al., 2013), and with our
previous study showing elevated tPA-inhibitor complexes in
the CSF of the most severe TBI patients (Sashindranath et al.,
2012).
Discussion
The loss of BBB integrity is a common feature of severe TBI
with nearly 50% of the patients examined in a recent study
showing biochemical evidence of BBB disruption (Ho et al.,
2014). Damage to the BBB can be immediate due to trauma-
induced hemorrhage (Logsdon et al., 2015), or can occur
rapidly following TBI in the absence of overt hemorrhage,
with significant increases in permeability observed within 3 h
of injury (Sashindranath et al., 2012). This early rise in BBB
permeability can affect the molecular injury pathways associated
with secondary brain injury in TBI, increasing cerebral edema
by disrupting parenchymal fluid homeostasis and by increasing
neuroinflammation (Shlosberg et al., 2010; Thal and Neuhaus,
2014; Logsdon et al., 2015). A principal focus in the management
of TBI is limiting the occurrence of cerebral edema and the
attendant increase in ICP (Hemphill and Phan, 2013a), therefore
targeting pathways that promote BBB disruption in TBI should
be beneficial. Our earlier studies demonstrating that the pathway
regulated by the protease tPA, acting through PDGF-CC and
the PDGFRα in the NVU, can promote pathologic increases
in BBB permeability (Yepes et al., 2000, 2003; Fredriksson
et al., 2004, 2005, 2015; Su et al., 2008; Abrams et al., 2012;
Adzemovic et al., 2013) led us to test the hypothesis that
treatment with Imatinib, an antagonist of the PDGFRα, could
reduce BBB permeability after TBI and improve outcomes.
Consistent with this hypothesis an earlier study has shown that
mice deficient in tPA have reduced BBB disruption 6 h after
injury, reduced edema 24 h after injury and smaller lesions 7 days
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FIGURE 4 | Imatinib reduces lesion volume and edema after Bi-lateral
TBI. Mice were treated with vehicle or Imatinib (200 mg/kg, twice daily p.o. for
5 days) starting 45 min after bilateral CCI and examined for lesion volume and
cerebral edema by MRI 24 h and 7 days after bilateral CCI. (A) Representative
T2-weighted MRI images. (B) Quantitative analysis of the lesion volume
determined from theT2-weighted hyper-intense signal. (C) The relative extent
of cerebral edema in both hemispheres was determined by calculating the
ADC values from DWI scans. Data are expressed as mean ± SEM (n = 4–5),
the single asterisk indicates p < 0.05, and the dotted line indicates the normal
ADC value of 736 × 10−3 mm2/s reported for age matched mice (Rau et al.,
2006).
following TBI (Mori et al., 2001). Whereas we have shown that
overexpression of tPA results in a significant increase in BBB
leakage and lesion volume 3 h after TBI (Sashindranath et al.,
2012).
Our data presented here demonstrate for the first time that
Imatinib dramatically reduces BBB permeability 24 h after TBI
by approximately 80% (Figure 1). This is similar to the extent of
BBB protection from Imatinib in a model of spinal cord injury
(Abrams et al., 2012) and even better than the approximately
30% reduction in BBB permeability we observed in stroke (Su
et al., 2008). Consistent with the view that BBB permeability
contributes to increased cerebral edema, Imatinib treatment
for 5 days also significantly reduced vasogenic edema in both
unilateral and bilateral injury models (Figures 2C, 4C). Imatinib
FIGURE 5 | Imatinib reduces tissue loss after Bi-lateral TBI. Mice were
treated with vehicle or Imatinib (200 mg/kg, twice daily p.o. for 5 days) starting
45 min after bilateral CCI. Twenty one days later, animals underwent MRI T2
scan and then were perfused and fixed in paraformaldehyde and stained with
H&E. (A,B) Representative photomicrographs of coronal sections near
bregma −1.5 (10× objective) from vehicle-treated (A) and Imatinib-treated (B)
mice. (C,D) Representative T2-weighted MRI images from vehicle-treated (C)
and Imatinib-treated mice (D). (E) Quantification of volumetric loss of tissue
determined from the T2-weighted hyper-intense signal. Data are expressed as
mean ± SEM (n = 5) and the single asterisk indicates p < 0.05.
also significantly reduced cytotoxic edema 24 h after injury in
the bilateral TBI model but was not significantly different from
vehicle in the unilateral model. This was likely because the milder
injury in the unilateral model produced less cytotoxic edema at
24 h than did the bilateral injury (unilateral 0.620± 0.043 mm2/s
vs. bilateral 0.559± 0.009 mm2/s).
The reductions in BBB permeability and cerebral edema
induced with Imatinib treatment were also correlated with
significant reductions in lesion size during the first week
following injury and with tissue preservation at 21 days after
CCI (Figures 2–5). Examination of the hematoxylin and eosin
stained sections demonstrated that Imatinib treatment was
remarkably effective at preserving brain tissue compared to the
vehicle treated mice. In fact in the vehicle treated mice the
loss of tissue due to vacuole formation or cavitation was so
extensive that it was not possible to quantify the magnitude
of tissue loss in either the unilateral or midline CCI model
(Figures 3, 5). Therefore, T2 MRI scans were utilized to quantify
the extent of cavitation after CCI and the effects of 5 days
of Imatinib treatment on tissue preservation. The preservation
of brain tissue at 21 days following injury is significant for
the long term recovery from TBI. Previous studies have shown
that neuronal tissue loss several weeks after injury, especially
in the hippocampus, is a common pathology in TBI that is
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FIGURE 6 | Imatinib improves neurological outcome in Morris Water Maze (MWM) after TBI. Imatinib ameliorates TBI associated impairments in spatial
learning and memory. (A) Cumulative proximity scores are plotted across 4 days of training for TBI (n = 7) and Sham (n = 9) treated mice. (B) Cumulative proximity
scores are plotted across 4 days of training for TBI mice treated with vehicle or Imatinib. (C) Average proximity during the probe trial which was completed 24 h after
the last training trial plotted for Sham and TBI treated mice. (D) Average proximity during the probe trial which was completed 24 h after the last training trial is
plotted for mice subjected to TBI and then treated with Imatinib (n = 8) or Vehicle (n = 7). (E) Cumulative proximity measured during the visible platform version of the
water maze is plotted for Sham and TBI treated mice. Data represent the average of 6 trials. (F) Cumulative proximity measured during the visible platform version of
the water maze is plotted for mice subjected to TBI and then treated with Imatinib or vehicle. (G) Swim speed measured during the probe trial in Sham and TBI
treated mice. (H) Probe trial swim speed of mice subjected to TBI and then treated with Imatinib or vehicle. Data are presented as mean ± SEM. Single asterisk in
(A,B) indicates p < 0.05 for main effect of treatment evaluated using a two-way repeated measures ANOVA with treatment and training days as factors. Single
asterisk in (C–H) indicates p < 0.05, two tailed unpaired t-test.
associated with memory deficit and cognitive decline (Witgen
et al., 2005). Our results demonstrate that Imatinib treatment
preserves significantly more tissue compared to vehicle including
tissue in the hippocampus. This is particularly apparent when
comparing Figures 5A,B. The exact mechanism by which 5 days
of Imatinib treatment is able reduce cavitation 21 days after
injury is uncertain. However, it is likely that early reduction
in BBB leakage together with the reductions in cerebral edema
achieved with Imatinib treatment contributed to reductions in
tissue loss.
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FIGURE 7 | Analysis of platelet derived growth factor-CC (PDGF-CC) in human TBI cerebrospinal fluid (CSF) samples. Human CSF Samples obtained
from patients within the first 24 h after TBI were immunoblotted for PDGF-CC. (A) Immunoblots from 17 TBI patients and nine controls are shown. As a control for
PDGF-CC a sample of releasate from human platelets is shown in the last lane of the first blot. The extended glasgow outcome scale (GOSE) score of each patient is
shown at the top of each lane (GOSE 1–8) and the position of molecular mass size markers are indicated at the left of each blot. (B) The relative amount of PDGF-CC
in each sample was estimated from the intensity of the PDGF-CC, assigned a value from 0 to 10 and the average for each GOSE score was plotted against the
GOSE score. The filled circles are the TBI samples and the open square represents the non-TBI samples. Each point is the mean ± SEM and the line is a linear
regression fit of the TBI samples, a Spearman’s correlation analysis of these data yields a one tailed p = 0.0292.
Behavioral impairment in the unilateral CCI model was not
consistently observed even in the vehicle treated mice. However,
midline cortical impact clearly disrupted performance in the
water maze. Compared to Sham treated mice, mice in the
TBI group exhibited significantly degraded search strategies
as measured by cumulative proximity during training and
average proximity during the probe trial. Treatment with
Imatinib significantly ameliorated these deficits. Injured mice
also exhibited, on average, slower swim speeds during the
probe trial and were impaired in the visible platform version
of the water maze. Interestingly, injured mice treated with
vehicle or Imatinib performed to the same level in the visible
platform task and did not differ with regard to their swim
speeds. Furthermore, performance in both groups appears to
be similar to that observed in the Sham treated mice. This
likely reflects the reduction in stress and anxiety produced by
the additional handling associated with the daily dosing of the
mice in the Imatinib experiment (Fridgeirsdottir et al., 2014).
Interpreted this way, these data would suggest that at least
some of the performance deficits observed in the TBI mice
may be more related to affective state and not due to deficits
in motor performance. This interpretation would be consistent
with previous work in the field demonstrating that TBI in mice
produces deficits in behavioral tests of anxiety-like behaviors
(Washington et al., 2012). In light of these observations we
conclude that Imatinib improves performance in the water maze
by ameliorating TBI associated cognitive impairments and not by
altering affective state or motor output.
Together, these data support the view that a dysfunctional
BBB and ensuing edema may contribute directly to TBI
progression including tissue loss and cognitive impairment,
and that treatment with Imatinib reduces these pathologic
effects in injured mice. Analysis of human CSF samples from
TBI patients suggests that PDGF-CC levels may correlate
with the extent of injury. Importantly though, it should
be noted that these data are semi-quantitative, and while
they suggest that this pathway could be active in human
TBI, additional studies will be needed to directly test this
hypothesis. Nonetheless, it is interesting to note that in
ischemic stroke patients treated with tPA there is a significant
positive association between increased plasma PDGF-CC and
hemorrhagic transformation (Rodríguez-González et al., 2013),
suggesting that in humans PDGF-CC may be linked to
cerebrovascular damage.
In conclusion, the data presented here support the
hypothesis that the PDGFRα pathway may play a role in
the loss of BBB integrity following TBI, and that inhibiting
this pathway may improve TBI outcomes. In addition, we
demonstrate the potential effectiveness of Imatinib, an existing
FDA approved antagonist of the PDGFRα pathway, for the
treatment of acute TBI, suggesting the possibility of the
relatively rapid translation of Imatinib into a clinical trial
in TBI.
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